

Appl. No. 09/703,809
Amdt. Dated February 20, 2004
Reply to Notice to Comply of January 22, 2004

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-85. (Canceled)

86. (currently amended) An isolated protein ~~TFIIA α / β -like factor protein~~, wherein the ~~protein comprises an amino acid sequence~~ having greater than 90% amino acid sequence identity to SEQ ID NO.: 2.

87. (previously presented) The isolated protein of claim 86, wherein the protein has greater than 95% amino acid sequence identity to SEQ ID NO.: 2.

88. (previously presented) The isolated protein of claim 86, wherein the protein has greater than 98% amino acid sequence identity to SEQ ID NO.: 2.

89. (previously presented) The isolated protein of claim 86, wherein the protein comprises an amino acid sequence of SEQ ID NO.: 2.

90. (currently amended) The isolated protein of claim 86, wherein the protein is tagged with a polyhistidine ~~epitope~~ tag.

91. (previously presented) The isolated protein of claim 86, wherein the protein is the product of in vitro translation.

92. (currently amended) An isolated ~~TFIIA α / β -like factor~~ protein encoded by a polynucleotide comprising a nucleic acid sequence ~~substantially homologous to the coding strand of the gene sequence~~ set forth in SEQ ID NO.: 1.

93. (currently amended) A fusion protein comprising ~~a portion of the TFIIA α / β -like factor~~ an isolated protein having greater than 90% sequence identity with SEQ ID NO.: 2 ~~protein of claim 7 and a non-TFIIA α / β -like factor fusion protein sequence~~.

94. (currently amended) The fusion protein of claim 93, wherein said ~~TFIIA α / β -like factor fusion protein sequence~~ further comprises an epitope tag.

95. (currently amended) The fusion protein of claim 93, wherein said ~~TFIIA α / β -like factor fusion protein sequence~~ further comprises a polyhistidine ~~epitope~~ tag.

Appl. No. 09/703,809
Amtd. Dated February 20, 2004
Reply to Notice to Comply of January 22, 2004

96. (currently amended) The fusion protein of claim 93, wherein said ~~non-TFIIA α / β -like factor~~ protein is a transcription factor.
97. (currently amended) An isolated ~~Stoned TFIIA α / β -like factor~~ protein, wherein the protein comprises an amino acid sequence having greater than 90% amino acid sequence identity to SEQ ID NO.: 4.
98. (previously presented) The isolated protein of claim 97, wherein the protein has greater than 95% amino acid sequence identity to SEQ ID NO.: 4.
99. (previously presented) The isolated protein of claim 97, wherein the protein has greater than 98% amino acid sequence identity to SEQ ID NO.: 4.
100. (previously presented) The isolated protein of claim 97, wherein the protein comprises an amino acid sequence of SEQ ID NO.: 4.
101. (currently amended) The isolated protein of claim 97, wherein the protein is tagged with a polyhistidine ~~epitope~~ tag.
102. (previously presented) The isolated protein of claim 97, wherein the protein is the product of in vitro translation.
103. (currently amended) An isolated ~~Stoned TFIIA α / β -like factor~~ protein encoded by a polynucleotide comprising a nucleic acid sequence ~~substantially homologous to the coding strand of the gene sequence~~ set forth in SEQ ID NO.: 3.
104. (currently amended) A fusion protein comprising a portion of the ~~Stoned TFIIA α / β -like factor~~ an isolated protein having greater than 90% sequence identity with SEQ ID NO.: 4 ~~protein of claim 18 and a non-TFIIA α / β -like factor~~ a fusion protein sequence.
105. (currently amended) The fusion protein of claim 104, wherein said ~~Stoned TFIIA α / β -like factor~~ fusion protein sequence ~~further~~ comprises an epitope tag.
106. (currently amended) The fusion protein of claim 104, wherein said ~~Stoned TFIIA α / β -like factor~~ fusion protein sequence ~~further~~ comprises a polyhistidine ~~epitope~~ tag.
107. (currently amended) The fusion protein of claim 104, wherein said ~~non-Stoned TFIIA α / β -like factor~~ protein is a transcription factor.

Appl. No. 09/703,809
Amdt. Dated February 20, 2004
Reply to Notice to Comply of January 22, 2004

This Response is filed within the one-month period, as such no fee is currently due.

Dated this February 20, 2004.

Respectfully submitted,

CHALKER FLORES, LLP

By: 

Edwin S. Flores
Attorney for Applicant
Registration No.: 38,453

Chalker Flores, LLP
Client No. 34,725
12700 Park Central, Ste. 455
Dallas, TX 75251
(214) 866 0001 Tel
(214) 866 0010 Fax